From Wikipedia, the free encyclopedia
Jump to: navigation, search
IUPAC name
Other names
Sarasar (US), SCH 66336
193275-84-2 N
ChEMBL ChEMBL298734 YesY
ChemSpider 130645 YesY
Jmol-3D images Image
KEGG D04768 YesY
PubChem 148195
Molar mass 638.82164
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N verify (what isYesY/N?)
Infobox references

Lonafarnib is a farnesyltransferase inhibitor (FTI) that is being investigated in a human clinical trial as a potential treatment for progeria.[1]

Lonafarnib is a synthetic tricyclic derivative of carboxamide with antineoplastic properties.[2] As such, it is used primarily for cancer treatment. For those with progeria, research has shown that the drug reduces the prevalence of stroke and transient ischemic attack, and the prevalence and frequency of headaches while taking the medication.[3] A phase II clinical trial was completed in 2012, which showed that a cocktail of drugs that included lonafarnib and two other drugs, met clinical efficacy endpoints that improved the height and diminished the rigidity of the bones of progeria patients.[citation needed]


  1. ^ Liu G; Marrinan CH; Taylor SA et al. (2007). "Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)". Anticancer Drugs 18 (8): 923–31. doi:10.1097/CAD.0b013e3280c1416e (inactive 2015-01-14). PMID 17667598. 
  2. ^ "Lonafarnib". NCI Drug Dictionary. National Cancer Institute. 
  3. ^ Ullrich, N. J.; Kieran, M. W.; Miller, D. T.; Gordon, L. B.; Cho, Y.-J.; Silvera, V. M.; Giobbie-Hurder, A.; Neuberg, D.; Kleinman, M. E. (2013). "Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment". Neurology 81 (5): 427–30. doi:10.1212/WNL.0b013e31829d85c0. PMC 3776537. PMID 23897869. 

See also[edit]

External links[edit]